Pralatrexate Demonstrates High Activity in Patients With Relapsed or Refractory Cutaneous-T-Cell Lymphoma: Presented at EHA

Doctor's Guide
DGDispatch
By Jenny Powers

BARCELONA, Spain -- June 15, 2010 -- Patients with cutaneous-T-cell lymphoma (CTCL) who failed prior systemic therapy responded to pralatrexate without experiencing significant toxicity, according to a study presented here at the 15th Congress of the European Hematology Association (EHA).
...

admin

ScienceDaily (Feb. 9, 2009) — Laboratory work in animals showed limited activity when statins were given to prevent breast cancer, according to a report in the February issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.

Statins, sold under brand names like Lipitor and Zocor, are primarily given to lower cholesterol and prevent heart disease, and prominent cardiologists almost universally agree that their use has changed the landscape....

admin